Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(80.0%)
Phase 2
1(20.0%)
5Total
Phase 1(4)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05693272Phase 1Completed

A Clinical Trial to Study the COVAC-1 Booster Dose in Generally Healthy Adults

Role: collaborator

NCT05226702Phase 1Completed

Clinical Trial to Study the COVAC-2 Booster Dose (for COVID-19) in Generally Healthy Adults.

Role: collaborator

NCT05209009Phase 2Completed

A Clinical Trial of COVAC-2 in Adults

Role: collaborator

NCT04702178Phase 1Completed

A Clinical Trial of COVAC-2 in Healthy Adults

Role: collaborator

NCT05155982Phase 1Withdrawn

A Clinical Trial of COVAC-1, a COVID-19 Vaccine, in Generally Healthy Adults

Role: collaborator

All 5 trials loaded